Assuming outcomes is required, the following 36 results were found.
-
seeks to further realize the Department’s mission by advancing its management and use of data to improve human health outcomes. It envisions data that is available, accessible, timely, equitable, meaningfully usable, and protected–and can be effectively...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Oncology
-
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
Navigators guide families through every step of their cancer journey. Navigators have been shown to improve health outcomes and the patient experience by reducing times between diagnosis and treatment and by increasing treatment completion. These...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Oncology
-
outcomes researchhttps://virustreatmentcenters.com/virustc/resources/glossary/outcomes-research
- Type: glossary
-
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Oncology
-
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Oncology
-
Administration announces funding for regenerative tissue project to restore immune system function and improve health outcomes through ARPA-H award The U.S. Department of Health and Human Services, through the Advanced Research Projects Agency for...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Oncology
-
- Type: glossary
-
- Type: glossary
-
- Type: glossary
-
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Oncology
-
also now know that this population is still advised to take precautions against COVID-19 due to the higher risk of serious outcomes like hospitalization, death, and long COVID. This is a group who also has access to public health tools like additional...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Medical News
-
from around the country in a colorectal cancer listening session to discuss ways to accelerate knowledge and improve outcomes for patients. The session, held in the Eisenhower Executive Office Building adjacent to the White House, was hosted by Danielle...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Oncology
-
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
Medicine shows that higher levels of T cells, which are cancer-fighting immune cells, are more likely to improve treatment outcomes for Merkel cell carcinoma. Higher levels of T cells are critical to the success of immune checkpoint inhibitors (ICIs)...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Oncology
-
therapy/apheresis. Her contributions led to significant improvements in patient care, staff engagement and operational outcomes. At Fred Hutch, Prophet-Williams will continue to move the center forward in pursuit of strategic goals. “My highest priority...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Oncology
-
studies conducted by Meiji during its development of tebipenem in Japan. In addition, available post-marketing outcomes data report the safety and efficacy of tebipenem in 3,540 pediatric patients with pneumonia, otitis media or sinusitis, and these...
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Pathology
-
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Oncology
-
- Type: Article
- Author: Dr. Correo “Cory” Andrew Hofstad J.S.D MPHJD MSPH JD Ph.D. M.D. D.O. MBACOGS MDiv
- Category: Oncology
Access Non-GMO, antigen-free, FDA-approved antiviral medication formulas used in Moderna's Spikevax.
VirusTC is a retail provider of concentrated FDA-approved antiviral medication formulas. VirusTC wholesale formulas are used in Moderna products. We sell FDA-approved formulas that are compatible with university medical plans, federal insurance coverage, and many major insurance providers. Our medications are part of tailored non-invasive cancer treatment plans available at a hospital in your region. VirusTC targets problems and provides care for the symptoms. Our products and services are used by Fred Hutch Cancer Center, John Hopkins, University Hospitals, the United States Military, and professional sports. During Operation Cancer Moonshot 2023, VirusTC products killed cancer cells, increased strength, and redeveloped muscles, tissue, and brain cells after cancer treatments.